International review of neurobiology
2025
Caitlin M. DuPont, Matthew W. Johnson
6 citations
The current chapter presents the literature evaluating the effects of classic psychedelic treatments on five substance use disorders: alcohol, tobacco, opioid, stimulant, and cannabis. Most work on psychedelics and substance use disorders was conducted for alcohol use disorder. A range of classic psychedelics (LSD, psilocybin, and ayahuasca) appear to be beneficial for facilitating both reduced...
Journal of Psychopharmacology
2025
Gianmarco Ingrosso, Anthony J. Cleare, Mario F Juruena
20 citations
Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians. This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression. A comprehensive search was...
Frontiers in Psychiatry
2025
Mary R. Shen, Dylan E Campbell, Anika Kopczynski et al.
10 citations
Opioid use disorder (OUD) continues to be a public health crisis in the United States, with mortality having doubled over the last twenty years, leading to significant economic cost, morbidity, and mortality. This has caused significant demand for novel therapeutics. Preliminary evidence demonstrates that ketamine may be helpful in treating OUD as well as serve as an adjunct during treatment of...
American Journal of Psychiatry
2025
Noam Goldway, Snehal Bhatt, Stephen Ross et al.
23 citations
PAT elicited durable shifts in personality, suggesting normalization of abnormal personality trait expression in AUD. Further study is needed to clarify whether PAT exerts its beneficial effects by reducing impulsiveness or whether impulsive individuals inherently respond better to PAT.
Journal of Meditation based Psychological Counseling
December 31, 2024
Kangsuk Shon
The purpose of this study is to qualitatively confirm the experience of participating in a temple stay-based smoking cessation meditation program. The research questions of this study are as follows. First, what motivated you to participate in the temple stay-based smoking cessation meditation program? Second, what helped this temple (Guryongsa) in quitting smoking? Third, how did meditation...
Journal of Psychopharmacology
December 17, 2024
Gianmarco Ingrosso, Anthony J. Cleare, Mario F Juruena
1 citation
Background: Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians. Aim: This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression. Methods: A...
Journal of Affective Disorders
December 15, 2024
Rodrigo Machado‐Vieira, Gregory H Jones, Alan C. Courtes et al.
Fatigue is a multidimensional condition that may overlap with depression. Initial studies found that fatigue responds in only a limited way to standard monoaminergic antidepressants and mood stabilizers but does respond positively to intravenous (IV) racemic (R,S)-ketamine (ketamine). However, IV ketamine's use is limited by cost and access barriers. To date, no study has evaluated intranasal...
Frontiers in Psychiatry
December 6, 2024
Jonathan Brett, Elizabeth Knock, Kathy Watson et al.
7 citations
Methamphetamine (MA) dependence leads to severe physical and psychological issues. Current treatments, including psychosocial therapies and residential rehabilitation, face limitations such as high relapse rates, cost, and accessibility issues. As a result, there is an urgent need for novel approaches to treat MA dependence that are effective, affordable, and accessible to patients. Psilocybin,...
Translational Psychiatry
December 5, 2024
Bettina Habelt, Dzmitry Afanasenkau, Cindy Schwarz et al.
6 citations
Patients with alcohol use disorder (AUD) who seek treatment show highly variable outcomes. A precision medicine approach with biomarkers responsive to new treatments is warranted to overcome this limitation. Promising biomarkers relate to prefrontal control mechanisms that are severely disturbed in AUD. This results in reduced inhibitory control of compulsive behavior and, eventually, relapse....
December 2, 2024
Arul Muthuvelu
This paper addresses the need to evaluate and update the evidence surrounding MBRP's effectiveness in treating substance use disorders (SUDs).Previous systematic reviews have assessed MBRP's efficacy, but with emerging research, there's a demand for a comprehensive overview of recent findings.Here, we aim to provide an updated synthesis of MBRP research, shedding light on its role in SUD...